A Study on the Efficacy and Safety of IPyC for HER2+ MBC
Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity. Efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR).
Breast Cancer
DRUG: Inetetamab and Pyrotinib Combined with Chemotherapy
progression-free survival (PFS), 2 years
objective response rate (ORR), 2 years|clinical benefit rate (CBR), 2 years
Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity. Efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR).